Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
|Articles|July 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
Hycamtin Approved For Ovarian Cancer
PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has received marketing clearance from the FDA for the treatment of patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy. It is the first topoisomerase I inhibitor approved for use in the United States.
Advertisement
PHILADELPHIA--SmithKline Beecham's Hycamtin (topotecan) has receivedmarketing clearance from the FDA for the treatment of patientswith metastatic ovarian cancer after failure of initial or subsequentchemotherapy. It is the first topoisomerase I inhibitor approvedfor use in the United States.
Hycamtin is currently available in pharmacies and will receiveits official launch by SmithKline shortly. (Look for a New Productreport next month).
The approval was based in part on results from an open, randomizedcomparative study showing that patients treated with Hycamtinhad a significantly longer progression-free survival than patientstreated with paclitaxel (Taxol) and a numerically superior responserate.
[For a more detailed discussion of the pivotal trials, see OncologyNews International, May, 1996,"Panel Recommende HycamtinApproval for Ovarian Cancer".]
Articles in this issue
over 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchover 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentover 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%over 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsover 30 years ago
Trimetrexate Appears Beneficial in Colorectal Cancerover 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsover 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyover 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataover 30 years ago
CDC Says Teen Smoking Still RisingAdvertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
3
Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist
4
ASCENT-03: Sacituzumab Govitecan Versus Chemotherapy in First-Line Metastatic TNBC
5